Literature DB >> 22045651

Novel comprehensive diagnostic strategy in Pitt-Hopkins syndrome: clinical score and further delineation of the TCF4 mutational spectrum.

Sandra Whalen1, Delphine Héron, Thierry Gaillon, Oana Moldovan, Massimiliano Rossi, Françoise Devillard, Fabienne Giuliano, Gabriela Soares, Michelle Mathieu-Dramard, Alexandra Afenjar, Perrine Charles, Cyril Mignot, Lydie Burglen, Lionel Van Maldergem, Juliette Piard, Salim Aftimos, Grazia Mancini, Patricia Dias, Nicole Philip, Alice Goldenberg, Martine Le Merrer, Marlène Rio, Dragana Josifova, Johanna Maria Van Hagen, Didier Lacombe, Patrick Edery, Sophie Dupuis-Girod, Audrey Putoux, Damien Sanlaville, Richard Fischer, Loïc Drévillon, Audrey Briand-Suleau, Corinne Metay, Michel Goossens, Jeanne Amiel, Aurelia Jacquette, Irina Giurgea.   

Abstract

Pitt-Hopkins syndrome (PTHS), characterized by severe intellectual disability and typical facial gestalt, is part of the clinical spectrum of Rett-like syndromes. TCF4, encoding a basic helix-loop-helix (bHLH) transcription factor, was identified as the disease-causing gene with de novo molecular defects. While PTHS appears to be a recognizable clinical entity, it seems to remain underdiagnosed, especially when facial gestalt is less typical. With the aim to facilitate the diagnosis of PTHS and to increase its rate and specificity, we have investigated 33 novel patients and defined a Clinical Diagnosis Score. Analysis of 112 individuals (79 previously reported and 33 novel patients) allowed us to delineate the TCF4 mutational spectrum, with 40% point mutations, 30% small deletions/insertions, and 30% deletions. Most of these were private mutations and generated premature stop codons. Missense mutations were localized in the bHLH domain, which is a mutational hotspot. No obvious difference was observed between patients harboring truncating, missense mutations, or deletions, further supporting TCF4 haploinsufficiency as the molecular mechanism underlying PTHS. In this study, we have summarized the current knowledge of TCF4 molecular pathology, reported all the mutations in the TCF4 database (http://www.LOVD.nl/TCF4), and present a novel and comprehensive diagnostic strategy for PTHS.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22045651     DOI: 10.1002/humu.21639

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  40 in total

1.  Pitt-Hopkins Mouse Model has Altered Particular Gastrointestinal Transits In Vivo.

Authors:  Vladimir Grubišić; Andrew J Kennedy; J David Sweatt; Vladimir Parpura
Journal:  Autism Res       Date:  2015-02-26       Impact factor: 5.216

Review 2.  Pitt-Hopkins Syndrome: A Review of Current Literature, Clinical Approach, and 23-Patient Case Series.

Authors:  Kimberly Goodspeed; Cassandra Newsom; Mary Ann Morris; Craig Powell; Patricia Evans; Sailaja Golla
Journal:  J Child Neurol       Date:  2018-01-10       Impact factor: 1.987

Review 3.  Transcription factor 4 (TCF4) and schizophrenia: integrating the animal and the human perspective.

Authors:  Boris B Quednow; Magdalena M Brzózka; Moritz J Rossner
Journal:  Cell Mol Life Sci       Date:  2014-01-12       Impact factor: 9.261

Review 4.  Connecting the CNTNAP2 Networks with Neurodevelopmental Disorders.

Authors:  Martin Poot
Journal:  Mol Syndromol       Date:  2015-02-03

Review 5.  Clinical review of genetic epileptic encephalopathies.

Authors:  Grace J Noh; Y Jane Tavyev Asher; John M Graham
Journal:  Eur J Med Genet       Date:  2012-01-25       Impact factor: 2.708

6.  Common Pathophysiology in Multiple Mouse Models of Pitt-Hopkins Syndrome.

Authors:  Courtney Thaxton; Alexander D Kloth; Ellen P Clark; Sheryl S Moy; Raymond A Chitwood; Benjamin D Philpot
Journal:  J Neurosci       Date:  2017-12-08       Impact factor: 6.167

7.  WNT/β-Catenin Pathway and Epigenetic Mechanisms Regulate the Pitt-Hopkins Syndrome and Schizophrenia Risk Gene TCF4.

Authors:  Krista M Hennig; Daniel M Fass; Wen-Ning Zhao; Steven D Sheridan; Ting Fu; Serkan Erdin; Alexei Stortchevoi; Diane Lucente; Jannine D Cody; David Sweetser; James F Gusella; Michael E Talkowski; Stephen J Haggarty
Journal:  Mol Neuropsychiatry       Date:  2017-07-14

Review 8.  Shining a light on CNTNAP2: complex functions to complex disorders.

Authors:  Pedro Rodenas-Cuadrado; Joses Ho; Sonja C Vernes
Journal:  Eur J Hum Genet       Date:  2013-05-29       Impact factor: 4.246

9.  Psychiatric Risk Gene Transcription Factor 4 Regulates Intrinsic Excitability of Prefrontal Neurons via Repression of SCN10a and KCNQ1.

Authors:  Matthew D Rannals; Gregory R Hamersky; Stephanie Cerceo Page; Morganne N Campbell; Aaron Briley; Ryan A Gallo; BaDoi N Phan; Thomas M Hyde; Joel E Kleinman; Joo Heon Shin; Andrew E Jaffe; Daniel R Weinberger; Brady J Maher
Journal:  Neuron       Date:  2016-03-10       Impact factor: 17.173

Review 10.  Pitt-Hopkins Syndrome and Differential Diagnosis: A Molecular and Clinical Challenge.

Authors:  Giuseppe Marangi; Marcella Zollino
Journal:  J Pediatr Genet       Date:  2015-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.